OPTIMISE Lung SABR

This study is a phase II multi-centre, randomised study independently evaluating five fraction Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) and three fraction IG-SABR for patients with a peripherally located T1-T2 and selected T3 and T4 lung tumours, or a peripherally located single pulmonary oligometastatic lesion.

Trial Details

NCT ID
NCT07777614
Phase
PHASE2
Sponsor
Cancer Trials Ireland
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment
  • Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR)
Locations (sample)
  • Dublin, Ireland|53.33306,-6.24889

Key Eligibility Criteria

  • Written informed consent obtained prior to any study-specific procedures.
  • ≥ 18 years of age.
  • Life expectancy \>6 months.
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →